Journal
NEUROTHERAPEUTICS
Volume 19, Issue 5, Pages 1588-1602Publisher
SPRINGER
DOI: 10.1007/s13311-022-01283-y
Keywords
Multivalent antibodies; Bispecific; A beta; Oligomers; BBB; Mouse models
Funding
- Uppsala University
- Swedish Research Council
- Hedlunds stiftelse
- Ake Wibergs stiftelse
- Ahlen-stiftelsen
- Jeanssons stiftelser
- Magnus Bergvallsstiftelse
- Vinnova
- Alzheimerfonden
- Konung Gustaf V:s och Drottning Victorias Frimuarestiftelse
- Hjarnfonden
- Gun and Bertil Stohne's Foundation
Ask authors/readers for more resources
In this study, a Bispecific-multivalent antibody format capable of passing the blood-brain barrier and targeting a wide range of sizes of soluble A beta aggregates was demonstrated.
Amyloid-beta (A beta) oligomers and protofibrils are suggested to be the most neurotoxic A beta species in Alzheimer's disease (AD). Hence, antibodies with strong and selective binding to these soluble A beta aggregates are of therapeutic potential. We have recently introduced HexaRmAb158, a multivalent antibody with additional A beta-binding sites in the form of single-chain fragment variables (scFv) on the N-terminal ends of A beta protofibril selective antibody (RmAb158). Due to the additional binding sites and the short distance between them, HexaRmAb158 displayed a slow dissociation from protofibrils and strong binding to oligomers in vitro. In the current study, we aimed at investigating the therapeutic potential of this antibody format in vivo using mouse models of AD. To enhance BBB delivery, the transferrin receptor (TfR) binding moiety (scFv8D3) was added, forming the Bispecific-multivalent antibody (HexaRmAb158-scFv8D3). The new antibody displayed a weaker TfR binding compared to the previously developed RmAb158-scFv8D3 and was less efficiently transcytosed in a cell-based BBB model. HexaRmAb158 detected soluble A beta aggregates derived from brains of tg-ArcSwe and App(NL-G-F) mice more efficiently compared to RmAb158. When intravenously injected, HexaRmAb158-scFv8D3 was actively transported over the BBB into the brain in vivo. Brain uptake was marginally lower than that of RmAb158-scFv8D3, but significantly higher than observed for conventional IgG antibodies. Both antibody formats displayed similar brain retention (72 h post injection) and equal capacity in clearing soluble A beta aggregates in tg-ArcSwe mice. In conclusion, we demonstrate a Bispecific-multivalent antibody format capable of passing the BBB and targeting a wide-range of sizes of soluble A beta aggregates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available